Limits...
Clinicopathologic significance of legumain overexpression in cancer: a systematic review and meta-analysis.

Zhen Y, Chunlei G, Wenzhi S, Shuangtao Z, Na L, Rongrong W, Xiaohe L, Haiying N, Dehong L, Shan J, Xiaoyue T, Rong X - Sci Rep (2015)

Bottom Line: Since reports on the clinical significance of legumain in cancer have shown inconsistent results, we systematically evaluated clinical indicators of legumain in cancer.Meta-analysis showed that legumain was overexpressed in cancer compared with in normal tissue and was higher in stage III-IV disease than in I-II disease.Moreover, legumain overexpression was correlated with poor prognosis and clinical stage.

View Article: PubMed Central - PubMed

Affiliation: Department of Tumor Molecular Biology, Nankai University School of Medicine, Tianjin 371000, China.

ABSTRACT
Since reports on the clinical significance of legumain in cancer have shown inconsistent results, we systematically evaluated clinical indicators of legumain in cancer. We searched the Cochrane Library, PubMed, Embase, and EBSCO databases and the Wangfang and CNKI databases in China by using "legumain" and ("neoplasms" OR "cancer") as search terms. We included case-controlled studies of legumain and cancer. The quality of the studies was evaluated by using Lichtenstein's guidelines, and valid data was extracted for analysis. In total, 10 articles were included in this study. Meta-analysis showed that legumain was overexpressed in cancer compared with in normal tissue and was higher in stage III-IV disease than in I-II disease. Moreover, legumain overexpression was correlated with poor prognosis and clinical stage. Furthermore, Cancer Genome Atlas data showed that among patients with rectal cancer, those with tumors overexpressing legumain had shorter overall survival than those in the low expression group (P < 0.05). Legumain appears to be involved in tumor development and deterioration; thus, it can potentially be developed into both a marker for monitoring and diagnosing tumors and a therapeutic target.

No MeSH data available.


Related in: MedlinePlus

Forest plot of risk ratios of legumain overexpression in cancer tissue vs normal tissue groups.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4660395&req=5

f1: Forest plot of risk ratios of legumain overexpression in cancer tissue vs normal tissue groups.

Mentions: Five articles compared LGMNHigh in cancer tissue and in normal tissue1319202223, including a total of 670 cancer cases (LGMNHigh: 51.9%) and 366 normal tissue samples (LGMNHigh: 13.4%). Since the studies were significantly heterogeneous (P < 0.10, I2 = 87%), we used a random-effect model for pooled analysis, which revealed significant differences between tumor tissues and normal tissues (RR = 3.32, 95% CI: 1.38–7.96, P < 0.05; Fig. 1). We analyzed each of the five articles individually. All five studies reported that LGMNHigh rates in cancer tissue were higher than in normal tissue. However, the sample sources were different and the research methods were not completely consistent, likely leading to heterogeneity (P < 0.10, I2 = 87%). Overall, in our meta-analysis, the LGMNHigh rate in cancer tissue was higher than that in normal tissue.


Clinicopathologic significance of legumain overexpression in cancer: a systematic review and meta-analysis.

Zhen Y, Chunlei G, Wenzhi S, Shuangtao Z, Na L, Rongrong W, Xiaohe L, Haiying N, Dehong L, Shan J, Xiaoyue T, Rong X - Sci Rep (2015)

Forest plot of risk ratios of legumain overexpression in cancer tissue vs normal tissue groups.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4660395&req=5

f1: Forest plot of risk ratios of legumain overexpression in cancer tissue vs normal tissue groups.
Mentions: Five articles compared LGMNHigh in cancer tissue and in normal tissue1319202223, including a total of 670 cancer cases (LGMNHigh: 51.9%) and 366 normal tissue samples (LGMNHigh: 13.4%). Since the studies were significantly heterogeneous (P < 0.10, I2 = 87%), we used a random-effect model for pooled analysis, which revealed significant differences between tumor tissues and normal tissues (RR = 3.32, 95% CI: 1.38–7.96, P < 0.05; Fig. 1). We analyzed each of the five articles individually. All five studies reported that LGMNHigh rates in cancer tissue were higher than in normal tissue. However, the sample sources were different and the research methods were not completely consistent, likely leading to heterogeneity (P < 0.10, I2 = 87%). Overall, in our meta-analysis, the LGMNHigh rate in cancer tissue was higher than that in normal tissue.

Bottom Line: Since reports on the clinical significance of legumain in cancer have shown inconsistent results, we systematically evaluated clinical indicators of legumain in cancer.Meta-analysis showed that legumain was overexpressed in cancer compared with in normal tissue and was higher in stage III-IV disease than in I-II disease.Moreover, legumain overexpression was correlated with poor prognosis and clinical stage.

View Article: PubMed Central - PubMed

Affiliation: Department of Tumor Molecular Biology, Nankai University School of Medicine, Tianjin 371000, China.

ABSTRACT
Since reports on the clinical significance of legumain in cancer have shown inconsistent results, we systematically evaluated clinical indicators of legumain in cancer. We searched the Cochrane Library, PubMed, Embase, and EBSCO databases and the Wangfang and CNKI databases in China by using "legumain" and ("neoplasms" OR "cancer") as search terms. We included case-controlled studies of legumain and cancer. The quality of the studies was evaluated by using Lichtenstein's guidelines, and valid data was extracted for analysis. In total, 10 articles were included in this study. Meta-analysis showed that legumain was overexpressed in cancer compared with in normal tissue and was higher in stage III-IV disease than in I-II disease. Moreover, legumain overexpression was correlated with poor prognosis and clinical stage. Furthermore, Cancer Genome Atlas data showed that among patients with rectal cancer, those with tumors overexpressing legumain had shorter overall survival than those in the low expression group (P < 0.05). Legumain appears to be involved in tumor development and deterioration; thus, it can potentially be developed into both a marker for monitoring and diagnosing tumors and a therapeutic target.

No MeSH data available.


Related in: MedlinePlus